Breaking Down SG&A Expenses: TG Therapeutics, Inc. vs Viking Therapeutics, Inc.

Biotech Giants' SG&A Expenses: A Decade of Strategic Growth

__timestampTG Therapeutics, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 2014245186921244910
Thursday, January 1, 2015198865805029636
Friday, January 1, 2016126316894846776
Sunday, January 1, 2017219779985329003
Monday, January 1, 2018207590007121000
Tuesday, January 1, 2019208380009128000
Wednesday, January 1, 202012181200010731000
Friday, January 1, 202115213700010701000
Saturday, January 1, 20228323100016121000
Sunday, January 1, 202312270600037021000
Loading chart...

Igniting the spark of knowledge

A Comparative Analysis of SG&A Expenses: TG Therapeutics vs. Viking Therapeutics

In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, TG Therapeutics, Inc. and Viking Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. TG Therapeutics has consistently outpaced Viking Therapeutics, with its SG&A expenses peaking at approximately 152 million in 2021, a staggering 900% increase from 2014. In contrast, Viking Therapeutics' expenses grew more modestly, reaching around 37 million in 2023, marking a 2900% increase from its 2014 figures. This disparity highlights TG Therapeutics' aggressive investment in administrative and sales functions, potentially reflecting a more expansive growth strategy. As the biotech sector continues to evolve, these financial insights offer a window into the strategic priorities of these two industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025